Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma
Authors Dong M, Miao L, Zhang F, Li S, Han J, Yu R, Qie S
Received 6 March 2018
Accepted for publication 8 May 2018
Published 28 June 2018 Volume 2018:11 Pages 3721—3729
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
Meng Dong,1 Lin Miao,2 Fengmei Zhang,3 Shengshui Li,3 Jingzhi Han,1 Ruohui Yu,1 Shuo Qie4
1Department of Hepatobiliary Surgery, Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei 061001, China; 2Departments of Obstetrics and Gynecology, Yixingbu Hospital, Beichen, Tianjin 300402, China; 3Department of Pathology, Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei 061001, China; 4Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
Background: Glutaminase (GLS), the key enzyme that catalyzes glutamine catabolism, facilitates the production of energy, building blocks, and factors resisting stresses. Two isoforms of GLS have been identified: GLS1 and GLS2. Elevated GLS1 contributes to tumorigenesis and tumor progression. This study investigates the molecular mechanism by which GLS1 is regulated in human hepatocellular carcinoma (HCC).
Methods: Online databases were investigated to search for factors that co-overexpress with GLS1. siRNA knockdown or chemical compounds were utilized to manipulate the activation or inactivation of nuclear factor-κB (NF-κB) p65 signaling. Both the mRNA and protein levels of GLS1 were detected. The biological and clinical importance of p65-GLS1 in HCC was also demonstrated.
Results: NF-κB p65 regulates GLS1 expression in HCC cells. Knockdown or suppression of GLS1 compromises HCC cell proliferation. Elevated GLS1 expression correlates with neoplasm histological grade, and the dysregulation of p65-GLS1 is associated with poor prognosis in human HCC patients.
Conclusion: GLS1 can be developed as a diagnostic and therapeutic target for human HCC.
Keywords: hepatocellular carcinoma, NF-κB p65, glutaminase, proliferation, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]